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Abstract
Background: Experimental studies have linked peritubular capillary (PTC) loss with progression of chronic kidney
disease. Minimal information on PTC in lupus nephritis (LN) has been reported. We therefore evaluated the PTC
area in different classes of LN and determined if specific clinical characteristics correlated with PTC changes.
Methods: Renal biopsies of 253 subjects with LN (categorized using the ISN/RPS 2003 classification) and 13 normal
renal donors (the controls) were retrospectively evaluated for PTC morphology by staining for CD31 with
immunohistochemistry method. The percent positive area of PTC (% PTC) was correlated with serum and
urinary measures of renal function and renal pathology.
Results: Significant PTC loss was observed in all classes of LN compared to controls. The % PTC area was
highest in controls (7.64±1.48 %) with levels of 1.95±1.50, 4.16±3.85, 4.19±4.45, 5.02±1.79, and 4.45±3.75 in
classes II, III, IV, IV combined with V and V, respectively (all p values < 0.05). The lowest PTC density was
observed in class II LN, but this may be because some cases with worse classes of LN showed increased PTC
density due to abnormally dilated capillaries associated with acute inflammation and angiogenesis. %PTC was
increased in those with hematuria (5.8±5.2 vs. 3.6±3.4 %, red blood cells 3-10 vs. < 3 cells/high power field,
p < 0.05) and was reduced in those with a moderately declined renal function (3.29±3.40 vs. 4.42±4.12,
eGFR 15-59 vs. ≥ 60 ml/min/1.73 m2, p < 0.05). Nephrotic-range proteinuria also trended to be associated with lower
PTC density although it did not reach statistical significance (3.1±2.6 vs. 4.9±4.5, p= 0.067).
Conclusions: LN is associated with PTC loss and the severity correlates with reduced renal function. Further studies are
needed to investigate whether a loss of PTC can predict long term renal outcomes in LN.
Keywords: Peritubular capillary, Lupus nephritis
Background
Lupus nephritis (LN) can present with diverse clinical
manifestations from asymptomatic proteinuria or
hematuria to nephrotic and nephritic syndromes. Im-
mune mediated renal injury can lead to local inflamma-
tion followed by progressive scarring from loss of
intrinsic renal parenchymal cells [1, 2]. Renal injury in
LN is known to affect glomerular, tubulointerstitial, and
vascular compartments [2, 3]. In 2003, the International
Society of Nephrology/Renal Pathology Society (ISN/
RPS) classified LN into 6 classes according to the re-
spective glomerular pathological characteristics [4, 5]. In
addition to the predominantly glomerular involvement
in LN, renal vascular lesions may affect glomerular capil-
laries, arterioles and arteries leading to thrombotic mi-
croangiopathy, lupus vasculopathy and lupus vasculitis
[3, 6–9], while tubulointerstitial injury manifests as
interstitial inflammation, renal tubular atrophy and/or
interstitial fibrosis [10, 11]. Several studies suggest that
the severity of vascular and tubulointerstitial injury in
LN predicts renal outcome [3, 6–12]. However, informa-
tion on the integrity of the peritubular capillaries (PTC),
which is the primary vascular supply for the renal tu-
bules, has been limited to date.
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Progressive PTC loss causes tubulointerstitial hypoxia
which induces the processes of inflammation, tubular
cell apoptosis and finally tubulointerstitial fibrosis [13].
Decreased PTC accompanied by declining renal function
has been reported in various human kidney diseases
(e.g., diabetic glomerulosclerosis, mesangioproliferative
glomerulonephritides, amyloidosis, benign nephrosclero-
sis and chronic interstitial nephritis) [14]. With renal in-
jury one may also observe transient increases in PTC
due to angiogenesis associated with acute inflammation,
as has been reported in kidneys associated with urinary
tract obstruction and reflux nephropathy and in mice
with reduced renal mass [15, 16].
Thacker et al. reported a decreased density of glom-
erular capillaries and PTC associated with down-
regulation of intrarenal vascular endothelial growth
factor-A (VEGF-A) in 20 renal biopsies of class II-V LN
patients [17]. Hayagawa et al. also reported a pattern of
peritubular capillaritis in a SLE patient presenting with
tubulointerstitial nephritis [18]. We therefore evaluated
a large cohort (>200 biopsies) of LN to determine the
nature of the PTC and whether there may be an associ-
ation with clinical characteristics or pathological classes
of LN. Our hypothesis was that PTC loss would be asso-
ciated with reduced renal function.
Methods
Study design
This was a cross-sectional retrospective study reported
according to the STROBE (STrengthening the Reporting
of OBservational studies in Epidemiology) guidelines.
Patients
The study included all of the patients ≥15 years of age
with renal pathologies diagnosed as LN at Srinagarind
Hospital, Khon Kaen, Thailand, between January 1, 2008
and December 31, 2011. The medical records and la-
boratory data collected during the two- week pre-biopsy
period were reviewed for clinical variables (including es-
timated glomerular filtration rate (eGFR), 24 h-urine
protein and urinalysis). The eGFR was calculated using
the Chronic Kidney Disease Epidemiology Collaboration
formula [19].
Renal histopathology
The renal biopsies were classified according to the
histological types of LN using the ISN/RPS 2003 classi-
fication. LN class VI was excluded from the study be-
cause there was only one specimen. The classes of LN
and severity of tubulointerstital damage were deter-
mined by the pathologist (AP) who was blinded to the
study. The extent of tubular atrophy in the renal cortex
and the areas of interstitial inflammatory cells infiltra-
tion and fibrosis were scored according to degree of
involvement: 0 (none); 1 (≤25 %); 2 (26–50 %), and 3
(>50 %). Thirteen renal biopsies obtained during im-
plantation of kidneys from deceased kidney donors
showing normal renal histology were used as the nor-
mal controls for PTC count.
Renal immunohistochemistry
Immunoperoxidase staining using anti-CD31 antibody
(to represent PTC) was performed on renal biopsies of
LN patients and the normal renal donors (the controls).
CD31, also known as PECAM-1 (platelet endothelial cell
adhesion molecule 1), is a 130-kDa transmembrane
glycoprotein and an endothelial marker. Previous studies
in patients with primary glomerulonephritis identified
differences in CD31 expression in glomerular capillaries
and PTC in various glomerular diseases [20–22]. Add-
itionally, Izmirly et al. performed immunoperoxidase of
anti-CD31 for evaluation the density of PTCs in the
renal cortex of LN patients [23].
Method of immunohistochemistry
Sections were deparafinized, rehydrated in a graded series
of ethanol, soaked in 3 % hydrogen-peroxide in methanol
for 5 min to block endogenous enzyme activity and
washed for 5 min with phosphate buffered saline (PBS).
Sections were subjected to antigen retrieval by immersing
them in 10 mM citrate buffer (pH 6), followed by micro-
wave treatment at heat level 10 (the highest) for 3 min
and level 3 (the mean) for 10 min. After completing the
cycles, the sections were allowed to cool at room
temperature (~25 °C) for 20 min then rinsed in running
tap water, distilled water, and PBS. After pre-treatment,
the sections were treated with PBS containing 3 % normal
horse serum at room temperature for 20 min, then incu-
bated with mouse anti- human CD31 protein dilution
1:100 (Neomarker, Labvision Corporation, USA), for 1 h
at room temperature. After washing with PBS, the sec-
tions were incubated with peroxidase-conjugated Envi-
sion™ antibody (DAKO, Glostrup, Denmark) for 30 min
and the color developed with 0.1 % diaminobenzidine tet-
rahydrochloride (DAB) solution. The sections were then
lightly counterstained with Mayer’s Haematoxylin, rinsed
in water for 3–4 min, dehydrated, cleared and mounted in
Permount®.
CD31 quantification
Slides were scanned at 20 ×magnification using a slide
scanner instrument (Scanscope XT S/N 1469, Aperio).
The scanned images were saved in 24-bit color TIFF for-
mat. The whole scan images were viewed at high reso-
lution using the Aperio System’s annotation software
(ImageScope 10, Aperio). Two pathologists (TT and
PM) used the ImageScope drawing tools to assess the
PTC positive area in a blinded fashion. The protocol of
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software (Positive Pixel Count, Aperio v9) was config-
ured to detect the number of pixels that show weak,
moderate and strong threshold limits in the brown col-
orimetric channel. Glomeruli, large vessels and fibrous
tissues were excluded from the selection. The percent
positive area of PTC (%PTC) was calculated using the
following equation: the total number of positive pixels
for CD31 at PTC divided by the total number positive
and negative of pixels multiplied by 100. The inter-rater
agreement of the two pathologists in quantification of
%PTC on 40 renal samples showed significant concord-
ance with a correlation coefficient of 0.96.
Statistical analyses
Statistical analyses comprised computing (a) the fre-
quency counts and percentages for the categorical vari-
ables and (b) the means and standard deviations for the
continuous variables. The two-tailed t test and ANOVA
were used to compare the continuous variables of the
two groups and multiple groups, respectively. Categor-
ical data were compared by the chi-squared and Fisher’s
exact test. Multivariate linear regression analysis was
performed by stepwise backward elimination to deter-
mine the clinical factors significantly associated with
changes in PTC. P-values < 0.05 were considered
statistically significant. All statistical analyses were
performed using SPSS for Windows version 17.0 and
STATA version 14.0.
Results
A total of 253 LN patients were included (83.8 % female).
The overall mean age was 33.7 ± 11.7 years (median
33 years with range 15 to 68 years). The histological types
and associated demographics are presented in Table 1. Ac-
cording to the ISN/RPS 2003 LN classification, there was
a respective 23, 6, 171, 3, and 50 cases in class II, III, IV,
IV combined with V (IV + V), and V. The mean SBP was
highest in the class IV group (140 ± 24 mmHg), whereas
the respective level in the class II, III, IV + V and V groups
was 129 ± 15, 134 ± 22, 125 ± 19 and 125 ± 16 mmHg.
Subjects with LN class IV group had a lower mean eGFR
than the other groups (i.e., 59 ± 38 mL/min/1.73 m2). The
24-h urine protein of patients in the class II (2.6 ± 1.5 g/d)
and III (1.9 ± 0.7 g/d) were lower than the class IV
(3.7 ± 2.9 g/d) and V (3.5 ± 2.1 g/d) groups. Micro-
scopic hematuria was more frequent in class III and
IV LN patients. Tubular atrophy, interstitial inflamma-
tory cell infiltration and interstitial fibrosis were high-
est in class IV LN patients (Table 1).
The mean age of thirteen normal controls was com-
parable with LN patients (31.4 ± 17.7 years) and the
range for PTC density (%PTC) was 6.02 - 9.90 % with
the mean of 7.64 ± 1.48 %. The %PTC of all LN classes
Table 1 Clinical data at the time of renal biopsy of lupus nephritis patients classified according to the ISN/RPS 2003. Data expressed













Age at biopsy (years) 34 ± 10 39 ± 14 33 ± 12 35 ± 10 36 ± 12
Male : Female (n) 3:20 2:4 27:144 0:3 9:41
SBP (mmHg) 129 ± 15 134 ± 22 140 ± 24b 125 ± 19 125 ± 16h
DBP (mmHg) 80 ± 9 86 ± 17 86 ± 16b 82 ± 16 80 ± 14
Blood urea nitrogen (mg/dL) 13.9 ± 6.9 33.0 ± 21.3a 41.9 ± 32.4b 21.4 ± 3.2c,g 19.4 ± 13.8d,f,h
Serum creatinine (mg/dL) 0.75 ± 0.21 1.60 ± 1.17a 1.92 ± 1.49b 0.83 ± 0.15g 0.80 ± 0.33f,h
eGFR (mL/min/1.73 m2) 109 ± 22 71 ± 44a 59 ± 38b 95 ± 25 102 ± 30f,h
Serum albumin (g/dL) 3.27 ± 0.54 3.20 ± 0.23 2.65 ± 0.81b,e 2.87 ± 0.81 2.81 ± 0.88
Serum complement (mg/dL)
C3 concentration 102 ± 47 108 ± 45 67 ± 102b 57 ± 28 97 ± 45h
C4 concentration 25 ± 18 26 ± 15 16 ± 18 8 ± 4c,g 22 ± 13h,i
Urinary protein (g/24 h) 2.60 ± 1.51 1.85 ± 0.70 3.69 ± 2.85b,e 3.23 ± 1.70 3.53 ± 2.05d,f
Urinary RBC (cells/HPF) 19 ± 39 45 ± 62 26 ± 35 4 ± 3g 4 ± 7d,f,h
Urinary WBC (cells/HPF) 10 ± 26 17 ± 30 13 ± 24 5 ± 8 3 ± 5f,h
Tubular atrophy scores (% of patients)&& 0/1/2 67/27/6 33/67/0 25/40/35 33/33/33 47/38/15
Interstitial inflammatory cells infiltration scores (% of patients)&& 0/1/2/3 71/29/0/0 33/33/17/17 28/58/12/2 33/33/33/0 77/23/0/0
Interstitial fibrosis scores (% of patients)&& 0/1/2/3 67/27/13/0 33/67/0/0 28/66/4/2 33/33/33/0 55/32/13/0
Notes: Estimated glomerular filtration rate calculated using the CKD-EPI creatinine 2009 formula. SBP; systolic blood pressure, DBP; diastolic blood pressure, eGFR;
estimated glomerular filtration rate, RBC; red blood cell, WBC; white blood cell, HPF; high power field. p < 0.05 aclass II vs. III, bII vs. IV, cII vs. IV + V, dII vs. V, eIII vs.
IV, fIII vs. V, gIV vs. IV + V, hIV vs. V, iIV + V vs. V. &&all p < 0.01 by Fisher’s exact test
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were lower than the controls (Fig. 1). LN class IV, IV + V
and V had significantly higher %PTC than class II (Figs. 1
and 2). The respective percentage of patients with de-
creased %PTC (<6.02 %), normal %PTC (6.02-9.90 %),
and increased %PTC (>9.90 %) was 100, 0,0 in class II
LN; 83, 0, 17 in class III LN; 76, 12, 12 in class IV LN,
67, 33, 0 in class IV + V, and 75, 9, 16 in class V LN. All
class II LN patients had a lower %PTC area than the
control group and morphologically the PTC were with-
out dilatation or abnormal features. In these subjects
the %PTC area positively correlated with eGFR. The
PTC of class IV or V LN patients who had normal or
high %PTC area, however, showed a distinctly abnormal
morphology; with the PTC being dilated and some
showing infiltrating mononuclear cells within and
around the PTC—a characteristic of peritubular capil-
laritis (Figs. 3 and 4). The class IV LN patients with
normal to increased %PTC also showed relatively worse
renal function than the reduced %PTC group (i.e., pro-
portion of severe decreased GFR, < 15 mL/min/
1.73 m2, 14.3 % vs. 6.5 %, p = 0.002). By comparison,
the class V LN patients with normal to increased %PTC
showed a higher degree of hematuria than the de-
creased %PTC participants (7.4 ± 8.2 vs. 1.7 ± 3.1 cells/
hpf, p = 0.002).
The following clinical factors were evaluated in rela-
tion to PTC loss by univariate analysis: age, sex, blood
pressure, eGFR, proteinuria, hematuria, pyuria, presence
of crescent, level of complements, and severity of tubu-
lointerstitial damage. Although some clinical factors
were significantly associated with % PTC changes, the
increase or decrease of PTC did not consistently correl-
ate with the severity of these factors. For example, the %
PTC area was increased in patients with modest micro-
scopic hematuria, e.g., % PTC in the mild hematuria
group (urine RBC 3–10 cells/hpf, %PTC 5.78 ± 5.17) was
Fig. 1 Percentage of peritubular capillaries in controls vs. various classes of LN. Notes: *p < 0.05 vs. class II, § p < 0.01 vs. controls
Fig. 2 CD31 expression in the peritubular capillaries (PTC) demonstrated in the control (a, %PTC = 7.6), class II LN patient (b, %PTC =2.0), class IV
LN patient (c, %PTC = 4.2) and class V LN patient (d, %PTC =4.5). Magnification 200×
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higher than in the no hematuria group (mean difference
2.22, 95 % CI 0.69 to 3.75, p = 0.005), but in the severe
microscopic hematuria groups (i.e., urine RBC > 30 cells/
hpf, %PTC 3.21 ± 3.91), %PTC was significantly de-
creased compared with the mild hematuria group (mean
difference −2.57, 95 % CI −4.33 to −0.82, p = 0.004).
In addition, the %PTC were lower in the eGFR
15–59 mL/min/1.73 m2 group compared to the
eGFR ≥ 60 mL/min/1.73 m2 group (mean difference 1.13,
95 % CI −2.26 to −0.01, p = 0.037). The %PTC was not,
however, further decreased in the severe decreased GFR
(<15 mL/min/1.73 m2) group.
Finally, the %PTC area trended to be lower in the pres-
ence of proteinuria, however, the change of %PTC also
depended on severity of proteinuria. The %PTC in the
mild proteinuria group (500–999 mg/day) appeared lower
than in the no proteinuria group, although this did not
reach statistical significance (mean difference −2.59, 95 %
CI −5.26 to 0.07, p = 0.057). The %PTC also trended to
decline in the severe proteinuria group (≥3,000 mg/d) vs.
the moderate proteinuria group (1000–1,999 mg/d) with a
mean difference of −1.22, 95 % CI −0.13 to 2.56, p = 0.076.
In addition, the %PTC was higher in subjects with
elevated diastolic blood pressure (DBP ≥ 100 mmHg)
group compared to the group with DBP < 80 mmHg
(mean difference 2.25, 95 % CI 0.27 to 4.23, p = 0.026).
Data are summarized in Fig. 5.
The results of multivariate linear regression analysis
identified LN classes, microscopic hematuria and renal
function to be significantly associated with PTC changes
(Table 2). When comparing the LN class II with class
III, IV and V, a statistically significant increase in %PTC
was found in classes IV (mean difference 2.43, 95 % CI
0.02 to 4.84, p < 0.05) and V (mean difference 2.46, 95 %
CI 0.02 to 5.00; p < 0.05) —likely due to the presence of
abnormal dilated vessels (angiogenesis) associated with
inflammation.
The %PTC area in the mild hematuria group was also
higher than the no hematuria group (mean difference
1.96, 95 % CI 0.25 to 3.67, p < 0.05). The eGFR 15–59 mL/
min/1.73 m2 group had a %PTC area that was lower than
the eGFR > 60 mL/min/1.73 m2 group (mean difference
−1.32, 95 % CI −2.62 to −0.02, p < 0.05). The %PTC
trended to be less in those with nephrotic-ranged protein-
uria group (mean difference −2.08, 95 % CI −4.31 to 0.15,
p = 0.067). The reason that no further decrease in %PTC
area was observed in the most severe GFR group (i.e.,
GFR < 15 mL/min/m2) may be due to the fact that all of
these subjects had class IV LN in which 42 % of them
showed normal to high %PTC, while only 12 % and 28 %
in the GFR 15–59 and GFR ≥ 60 mL/min/1.73 m2 group
revealed normal to high %PTC (p = 0.005). Furthermore,
the %PTC area in the mild hematuria group was highest
because it had the greatest proportion of participants who
exhibited normal to high %PTC, especially class V LN pa-
tients (i.e., 35 % in this group vs. 15–16 % in other degree
of hematuria groups, p = 0.014). A subgroup analysis of
class V LN patients showed 72, 21 and 7 % of them had
urine RBC < 3, 3–10 and 10–30 cells/hpf, respectively.
Mean %PTC of the urine RBC 3–10 cells/hpf group was
Fig. 3 The control revealed normal % PTC (a), some cases of class IV LN (b) and class V LN (c) demonstrated high %PTC with abnormal
morphology of dilated PTC. (Magnification 200×)
Fig. 4 Figures a and b—the magnification figure of a—represented the dilated PTC and some demonstrated mononuclear cell infiltration within
and around the PTC, the characteristic of peritubular capillaritis. (Magnification 200× for Figure a and 400× for Figure b)
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significantly higher than those with urine RBC < 3 cells/
hpf group (7.33 ± 4.81 vs. 3.51 ± 3.02, p = 0.006).
Discussion
In this study we performed an analysis of over 250 renal
biopsies from patients with lupus nephritis in order to
test the hypothesis that a reduction in PTC (as noted by
PTC density) would be associated with worse renal func-
tion. While a prior study had reported a reduction in
PTC in LN, the study consisted of 20 biopsies [17] and
hence we deemed it important to evaluate a larger sam-
ple. Several key findings were noted. First, we confirmed
that PTC was reduced in all classes of LN. Second, we
found that subjects with stage 3–4 CKD showed more
Fig. 5 Univariate analysis of the various clinical factors associated with %PTC Notes: RBC; red blood cells, HPF; high power field, eGFR (estimated
glomerular filtration rate) defined according to CKD-EPI formula, *included LN class IV + V
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PTC loss than those with CKD stage 2. Finally, we
found a tendency for less PTC in subjects with neph-
rotic range proteinuria. These data generally agree
with studies in other glomerular diseases that confirm
a relationship with lower PTC and severity of renal
disease [14, 21, 24–28].
One of our most important findings was that there
was a 40–50 % reduction in PTC in biopsies from LN
compared to healthy controls. One aspect of this is that
subjects with class II LN showed some of the greatest
loss of PTC, which is surprising as they are considered
to have relatively mild disease compared to class IV and
V LN. However, a review of the biopsies showed that
while a loss of PTC is commonly observed in LN, in ap-
proximately 25 % of subjects with more severe classes of
LN, there was evidence for marked renal inflammation
and de novo angiogenesis as noted by the presence of
atypical dilated capillaries and capillaritis. This latter
finding is typical for neoangiogenesis and has been noted
in some models of kidney disease [15, 16]. This is likely
due to a period of increased VEGF-A expression during
acute inflammation as macrophages are a rich source of
cytokine-induced VEGF-A [29, 30]. Although decreased
renal VEGF-A expression has been reported in some LN
patients as postulated to be a consequence of podocyte
injury [17, 31, 32]—some subjects with LN show in-
creased serum and urine VEGF-A levels and increased
renal VEGF-A expression [33–37].
Interestingly, the subjects with the increase in PTC
due to abnormal angiogenesis did not have preserved
renal function, but rather demonstrated worse renal
function within their class. Indeed, these subjects
showed more severely declined GFR in class IV LN and
greater hematuria in class V LN groups. It seems likely
that the injury is more severe as a consequence of both
greater inflammation [38] while the presence of abnor-
mal vessels and capillaritis may not translate into im-
proved blood flow to the damaged kidney. Consistent
with these findings is the report of peritubular capillari-
tis with tubulointerstitial nephritis in a SLE patient [18].
In our study, subjects with nephrotic-range proteinuria
trended to show a greater reduction of PTC. Katavetin
et al. proposed that the loss of PTC could be secondary
to albuminuria associated reduction in renal tubular
VEGF-A production [39]. Nevertheless, we also observed
a loss of PTC in subjects with Class II LN that have rela-
tively mild proteinuria. This suggests other mechanisms
may be driving PTC loss in these patients. It is of inter-
est that one study reported that a loss of PTC was also
high in subjects with mesangial proliferative nephritis
Table 2 Multivariate analysis of the clinical factors associated with percent of PTC change
Clinical factors %PTC (Mean ± SD) Unadjusted mean difference
(95 % Confidence interval)
Adjusted mean difference
(95 % Confidence interval)
p-value
LN classes
II 1.95 ± 1.50 Reference Reference
III 4.16 ± 3.85 2.21 (−1.54 to 5.96) 2.67 (−1.79 to 7.13) 0.239
IVa 4.20 ± 4.41 2.25 (0.11 to 4.39) 2.43 (0.02 to 4.84) 0.042**
V 4.45 ± 3.75 2.59 (0.11 to 4.88) 2.46 (0.02 to 5.00) 0.047**
Hematuria (cells/HPF)
<3 3.55 ± 3.35 Reference Reference
3–10 5.78 ± 5.17 2.22 (0.69 to 3.75) 1.96 (0.25 to 3.67) 0.025**
10–30 4.69 ± 4.65 1.13 (−0.50 to 2.77) 0.92 (−1.03 to 2.88) 0.353
>30 3.21 ± 3.91 −0.35 (−1.84 to 1.15) −0.11 (−1.92 to 1.70) 0.904
eGFR (mL/min/1.73 m2)
≥60 4.42 ± 4.12 Reference Reference
15–59 3.29 ± 3.40 −1.13 (−2.26 to −0.01) −1.32 (−2.62 to-0.02) 0.046**
<15 5.09 ± 4.72 0.66 (−1.67 to 3.00) −0.18 (−2.70 to 2.34) 0.117
Urinary protein (mg/day)
<500 4.90 ± 4.46 Reference Reference
500–999 2.31 ± 1.69 −2.59 (−5.26 to 0.07) −2.45 (−5.17 to 0.27) 0.077
1,000–1,999 4.35 ± 4.09 −0.55 (−2.90 to 1.80) −1.04 (−3.47 to 1.39) 0.399
2,000–2,999 3.89 ± 3.86 −1.02 (−3.33 to 1.30) −1.36 (−3.79 to 1.07) 0.269
≥3,000 3.14 ± 2.64 −1.77 (−3.96 to 0.43) −2.08 (−4.31 to 0.15) 0.067
Notes: %PTC; percentage of peritubular capillary, eGFR; estimated glomerular filtration rate, calculated according to CKD-EPI formula
aincluded LN class IV + V, **statistical significant p < 0.05
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compared to other, more severe forms of GN [21].
Again, this may relate to the potential for inflammatory
diseases and the extent of renal damage to undergo an
initial increase in neovessels with inflammation prior to
a loss of PTC as the kidney disease advances [16]. It is
possible that milder diseases bypass this initial inflam-
matory expansion of capillaries. Additionally, some class
II LN patients may be transformed from class III, IV or
V LN groups after treatment thus the inflammation has
already diminished. To confirm this hypothesis, serial
changes in the PTC should be analyzed in association
with changes in VEGF-A, inflammation and fibrosis.
Limitations of the study include its cross-sectional na-
ture. Confirmation of CD31 expressed on PTC with the
other endothelial markers such as CD34 or Ki67 was not
performed due to limited samples and would have been
useful as a second marker for endothelial cells or endo-
thelial cell proliferation. A strength of this study is the
large number of biopsies studied and the masked quanti-
fication of the PTC area by two pathologists (correlation
coefficient of 0.96).
Conclusions
PTC loss is common in LN. Some subjects, particularly
with more severe LN, may show evidence for increased
angiogenesis in the setting of increased inflammation.
Both overall PTC loss, as well as increased neoangiogen-
esis, are associated with worse renal function. Our study
emphasizes the importance of PTC in glomerular disease
and in subjects with LN. Further study is needed to
understand the mechanisms and mediators regulating
angiogenesis in LN patients.
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